Free Trial

What is Cormark's Estimate for Cresco Labs FY2024 Earnings?

Cresco Labs logo with Medical background

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Analysts at Cormark decreased their FY2024 earnings per share (EPS) estimates for Cresco Labs in a research report issued on Monday, November 11th. Cormark analyst J. Pytlak now forecasts that the company will earn ($0.21) per share for the year, down from their previous estimate of ($0.17). Cormark has a "Hold" rating on the stock. The consensus estimate for Cresco Labs' current full-year earnings is ($0.19) per share. Cormark also issued estimates for Cresco Labs' FY2025 earnings at $0.03 EPS.

CRLBF has been the topic of several other reports. Ventum Cap Mkts raised Cresco Labs to a "strong-buy" rating in a research report on Friday, August 9th. Roth Capital upgraded shares of Cresco Labs to a "strong-buy" rating in a research note on Sunday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $2.50.

Read Our Latest Report on Cresco Labs

Cresco Labs Trading Up 14.3 %

CRLBF stock traded up $0.18 on Thursday, hitting $1.44. 919,928 shares of the company were exchanged, compared to its average volume of 752,714. Cresco Labs has a twelve month low of $1.02 and a twelve month high of $2.65. The business's fifty day moving average is $1.58 and its two-hundred day moving average is $1.70. The stock has a market capitalization of $702.92 million, a price-to-earnings ratio of -7.20 and a beta of 1.88. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30.

Cresco Labs Company Profile

(Get Free Report)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

See Also

Earnings History and Estimates for Cresco Labs (OTCMKTS:CRLBF)

Should you invest $1,000 in Cresco Labs right now?

Before you consider Cresco Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.

While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Hershey’s Dividend Growth: A Sweet Pick for Investors

Hershey's isn't just a household name; it's a reliable pick for dividend growth, now up 15% this year and a 3-year average annualized 12.2% return.

Related Videos

Inflation-Busting Dividends: 3 Stocks Raising Payouts 4X Faster

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines